FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2145761690> ?p ?o ?g. }

• W2145761690 endingPage "135" @default.
• W2145761690 startingPage "133" @default.
• W2145761690 abstract "In the article that accompanies this editorial, Mackey et al present the results of ROSE/TRIO-12, a randomized phase III trial comparing single agent docetaxel to the combination of docetaxel and ramucirumab in front-line metastatic breast cancer. This large, wellpowered, placebo-controlled international trial replaced bevacizumab (a vascular endothelial growth factor [VEGF] –A ligand blocking antibody used in numerous phase III trials) with ramucirumab (a human immunoglobulin G1 VEGF receptor [VEGFR] –2–binding monoclonal antibody recently approved for gastric cancer) as the anti-VEGF agent to be studied. The results are disappointing but familiar to those who have followed the story of anti-VEGF therapy in breast cancer—yet another failure. Bevacizumab, the first anti-VEGF therapy to enter the breast cancer arena, electrified the field in 2005 with the E2100 trial, which showed a doubling in progression-free survival (PFS) when combined with weekly paclitaxel. Two subsequent trials (AVADO [Phase III Trial of Avastin and Docetaxel] and RIBBON-1 [Regimens in Bevacizumab for Breast Oncology]) combined bevacizumab with docetaxel, and while neither demonstrated the same degree of PFS benefit as the initial trial, all three demonstrated statistically significant improvements in PFS. These trials were based on a substantial body of preclinical and clinical evidence suggesting the centrality of angiogenesis in general, and VEGF in particular, to breast cancer growth, invasion, and metastasis. Increased tumor VEGF was associated with impaired outcome in numerous clinical studies, and inhibition of VEGF in preclinical models (alone or in combination with other chemotherapeutics and biologics) was associated with improved outcome. Taxanes are imbued with their own antiangiogenic activity, and the combination of taxanes with bevacizumab in particular appeared to provide synergistic antitumor activity in preclinical models of breast cancer. Things went downhill from the initial presentation of the first three randomized trials. After the approval of bevacizumab for metastatic breast cancer by the US Food and Drug Administration (following a contentious ODAC meeting), mature survival results demonstrated that the three trials (individually and collectively) failed to demonstrate an overall survival advantage. Bevacizumab, the beneficiary of an accelerated approval based on initial results, lost its breast cancer label in the United States. Other failures followed. An ambitious adjuvant program was launched, based on the original disease-free survival results. The main results of these large adjuvant trials are now in, and like the metastatic trials, they disappoint. Whether the anti-VEGF hypothesis was tested in a general population (E5103), a human epidermal growth factor receptor 2 (HER2) –positive population (BETH [Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab]) or in triplenegative breast cancer (BEATRICE [A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer]) the results were the same: no statistically significant improvement in disease-free survival was seen. Was this failure a failure of bevacizumab, or of the underlying anti-VEGF hypothesis for breast cancer? This is a reasonable question to ask: we do not always get it right with the first drug to target a malignant process. Sunitinib, a small molecule receptor tyrosine kinase inhibitor of VEGFR2 (and many, many other kinases) struck out in multiple phase III trials in metastatic breast cancer, despite interesting phase II monotherapy results. And now ramucirumab joins the list of failed attempts to use anti-VEGF therapy in metastatic breast cancer. Ramucirumab is a human immunoglobulin G1 monoclonal antibody that binds the extracellular domain of VEGFR-2, as opposed to bevacizumab’s ligand-binding qualities. While there was a numerically increased PFS resulting from the addition of ramucirumab to docetaxel (from 8.2 to 9.5 months), this did not reach statistical significance (P .077), and failed to prolong overall survival (27.3 v 27.3 months). The drug, in addition, added significantly more toxicity, in the form of increased rates of fatigue, hypertension, febrile neutropenia, hand-foot syndrome, and stomatitis. The US Food and Drug Administration approved ramucirumab for use in gastric cancer, where it (albeit modestly) improves both PFS and overall survival. So once again (as with bevacizumab and sunitunib) this seems a breast cancer failure rather than a general failure for the anti-VEGF hypothesis. Since ramucirumab, like bevacizumab and sunitunib, target essentially the same process (VEGF-driven angiogenesis) in the same disease, its failure is perhaps unsurprising. But why has VEGF-based therapy for breast cancer, which began with such promise, failed so completely? In particular, why has the improvement seen in PFS seen with bevacizumab (and at least hinted at with ramucirumab) not translated to an improvement in overall survival in the metastatic setting, or in disease-free survival in the adjuvant setting? JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L VOLUME 33 NUMBER 2 JANUARY 1" @default.
• W2145761690 created "2016-06-24" @default.
• W2145761690 creator A5066769011 @default.
• W2145761690 date "2015-01-10" @default.
• W2145761690 modified "2023-10-17" @default.
• W2145761690 title "Anti–Vascular Endothelial Growth Factor Therapy in Breast Cancer: Game Over?" @default.
• W2145761690 cites W1522653250 @default.
• W2145761690 cites W1554296669 @default.
• W2145761690 cites W1978291661 @default.
• W2145761690 cites W2039212876 @default.
• W2145761690 cites W2039335375 @default.
• W2145761690 cites W2055192249 @default.
• W2145761690 cites W2067969350 @default.
• W2145761690 cites W2085946496 @default.
• W2145761690 cites W2098276344 @default.
• W2145761690 cites W2098516378 @default.
• W2145761690 cites W2099824657 @default.
• W2145761690 cites W2103551875 @default.
• W2145761690 cites W2103563357 @default.
• W2145761690 cites W2103979740 @default.
• W2145761690 cites W2104759721 @default.
• W2145761690 cites W2126275851 @default.
• W2145761690 cites W2131705241 @default.
• W2145761690 cites W2132046158 @default.
• W2145761690 cites W2135530224 @default.
• W2145761690 cites W2144574890 @default.
• W2145761690 cites W2149037161 @default.
• W2145761690 cites W2167224460 @default.
• W2145761690 cites W2169435545 @default.
• W2145761690 cites W2275088062 @default.
• W2145761690 cites W2461425243 @default.
• W2145761690 doi "https://doi.org/10.1200/jco.2014.58.1298" @default.
• W2145761690 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25349299" @default.
• W2145761690 hasPublicationYear "2015" @default.
• W2145761690 type Work @default.
• W2145761690 sameAs 2145761690 @default.
• W2145761690 citedByCount "43" @default.
• W2145761690 countsByYear W21457616902014 @default.
• W2145761690 countsByYear W21457616902015 @default.
• W2145761690 countsByYear W21457616902016 @default.
• W2145761690 countsByYear W21457616902017 @default.
• W2145761690 countsByYear W21457616902018 @default.
• W2145761690 countsByYear W21457616902019 @default.
• W2145761690 countsByYear W21457616902020 @default.
• W2145761690 countsByYear W21457616902022 @default.
• W2145761690 countsByYear W21457616902023 @default.
• W2145761690 crossrefType "journal-article" @default.
• W2145761690 hasAuthorship W2145761690A5066769011 @default.
• W2145761690 hasBestOaLocation W21457616901 @default.
• W2145761690 hasConcept C121608353 @default.
• W2145761690 hasConcept C126322002 @default.
• W2145761690 hasConcept C143998085 @default.
• W2145761690 hasConcept C167734588 @default.
• W2145761690 hasConcept C2777025900 @default.
• W2145761690 hasConcept C502942594 @default.
• W2145761690 hasConcept C530470458 @default.
• W2145761690 hasConcept C71924100 @default.
• W2145761690 hasConceptScore W2145761690C121608353 @default.
• W2145761690 hasConceptScore W2145761690C126322002 @default.
• W2145761690 hasConceptScore W2145761690C143998085 @default.
• W2145761690 hasConceptScore W2145761690C167734588 @default.
• W2145761690 hasConceptScore W2145761690C2777025900 @default.
• W2145761690 hasConceptScore W2145761690C502942594 @default.
• W2145761690 hasConceptScore W2145761690C530470458 @default.
• W2145761690 hasConceptScore W2145761690C71924100 @default.
• W2145761690 hasIssue "2" @default.
• W2145761690 hasLocation W21457616901 @default.
• W2145761690 hasLocation W21457616902 @default.
• W2145761690 hasOpenAccess W2145761690 @default.
• W2145761690 hasPrimaryLocation W21457616901 @default.
• W2145761690 hasRelatedWork W1614920087 @default.
• W2145761690 hasRelatedWork W1992323317 @default.
• W2145761690 hasRelatedWork W1994121259 @default.
• W2145761690 hasRelatedWork W2034766187 @default.
• W2145761690 hasRelatedWork W2111462424 @default.
• W2145761690 hasRelatedWork W2153470798 @default.
• W2145761690 hasRelatedWork W2224319365 @default.
• W2145761690 hasRelatedWork W2359250635 @default.
• W2145761690 hasRelatedWork W2412682088 @default.
• W2145761690 hasRelatedWork W377899687 @default.
• W2145761690 hasVolume "33" @default.
• W2145761690 isParatext "false" @default.
• W2145761690 isRetracted "false" @default.
• W2145761690 magId "2145761690" @default.
• W2145761690 workType "article" @default.